ICU Medical, Inc. (NASDAQ:ICUI) Shares Sold by Rhumbline Advisers

Rhumbline Advisers reduced its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 0.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 65,015 shares of the medical instruments supplier’s stock after selling 433 shares during the quarter. Rhumbline Advisers owned 0.27% of ICU Medical worth $10,725,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in ICU Medical by 8.8% during the first quarter. Vanguard Group Inc. now owns 2,122,104 shares of the medical instruments supplier’s stock worth $472,466,000 after buying an additional 171,851 shares during the period. Wellington Management Group LLP grew its position in shares of ICU Medical by 71.6% in the first quarter. Wellington Management Group LLP now owns 1,516,089 shares of the medical instruments supplier’s stock valued at $337,542,000 after purchasing an additional 632,609 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of ICU Medical by 1.1% in the fourth quarter. JPMorgan Chase & Co. now owns 754,421 shares of the medical instruments supplier’s stock valued at $118,806,000 after purchasing an additional 8,256 shares during the last quarter. Morgan Stanley grew its position in shares of ICU Medical by 233.5% in the fourth quarter. Morgan Stanley now owns 679,912 shares of the medical instruments supplier’s stock valued at $107,073,000 after purchasing an additional 476,012 shares during the last quarter. Finally, Victory Capital Management Inc. grew its position in shares of ICU Medical by 4,680.7% in the first quarter. Victory Capital Management Inc. now owns 597,877 shares of the medical instruments supplier’s stock valued at $98,626,000 after purchasing an additional 585,371 shares during the last quarter. 91.49% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ICUI shares. 51job reiterated a “maintains” rating on shares of ICU Medical in a research report on Tuesday, May 9th. KeyCorp upped their price objective on shares of ICU Medical from $200.00 to $216.00 in a research note on Tuesday, May 9th. Finally, StockNews.com began coverage on shares of ICU Medical in a research note on Thursday, August 17th. They set a “hold” rating on the stock.

Insider Activity

In other news, CEO Vivek Jain sold 30,000 shares of the firm’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $180.02, for a total value of $5,400,600.00. Following the transaction, the chief executive officer now owns 23,677 shares of the company’s stock, valued at approximately $4,262,333.54. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Elisha W. Finney sold 194 shares of the firm’s stock in a transaction on Wednesday, June 7th. The shares were sold at an average price of $190.41, for a total transaction of $36,939.54. Following the completion of the sale, the director now directly owns 1,481 shares of the company’s stock, valued at approximately $281,997.21. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Vivek Jain sold 30,000 shares of the firm’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $180.02, for a total transaction of $5,400,600.00. Following the sale, the chief executive officer now directly owns 23,677 shares of the company’s stock, valued at $4,262,333.54. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 60,194 shares of company stock valued at $11,097,640. Company insiders own 7.50% of the company’s stock.

ICU Medical Stock Performance

Shares of ICUI opened at $144.86 on Monday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.97 and a current ratio of 2.57. The company has a market capitalization of $3.50 billion, a price-to-earnings ratio of -71.71 and a beta of 0.63. The company’s 50 day simple moving average is $161.88 and its 200 day simple moving average is $171.68. ICU Medical, Inc. has a 1 year low of $128.90 and a 1 year high of $212.43.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings results on Monday, August 7th. The medical instruments supplier reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.43. The company had revenue of $549.31 million for the quarter, compared to the consensus estimate of $562.90 million. ICU Medical had a negative net margin of 2.11% and a positive return on equity of 6.93%. On average, sell-side analysts predict that ICU Medical, Inc. will post 5.14 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters.